RESUMEN
Objective: To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 COVID-19 and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method(s): The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group,and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms,disappearance time of main symptoms,efficacy on traditional Chinese medicineTCMsymptoms,hospitalization duration,laboratory test indicators,and CT imaging changes in the two groups were compared. Result(s): The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment,the disappearance rate of fever,cough, fatigue,dry throat,anorexia,poor mental state,and poor sleep quality in the observation group was higher than that in the control groupP<0.05,and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms,the main symptomsfever, cough,fatigue,dry throat,anorexia,chest distressdisappeared earlier in the observation group than in the control groupP<0.01. After 7 days of treatment,the scores of the TCM symptom scale of both groups decreasedP<0.01,and the decrease of the observation group was larger that of the control groupP<0.01. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group12.79+/-2.68dwas shorter than that in the control group15.27+/-3.11dP<0.01. The effective rate in the observation group92.31%,24/26was higher than that in the control group76.92%,20/26. After 7 days of treatment,the lymphocyteLYMcount increasedP<0.05,and white blood cellWBCcount and neutrophilNEUTcount decreased insignificantly in the two groups. Moreover,levels of C-reactive protein CRP,erythrocyte sedimentation rateESR,and procalcitoninPCTreduced in the two groups after treatmentP<0.01and the reduction in the observation group was larger than that in the control group P<0.01. Through 7 days of treatment,the total effective rate on pulmonary shadow in the observation group 90.00%,18/20was higher than that in the control group77.27%,17/22P>0.05and the improvement of lung shadow in the observation group was better than that in the control groupP<0.01. Conclusion(s):Modified Sanxiaoyin can significantly alleviate fever,cough,fatigue,anorexia,chest distress,poor sleep quality,and other symptoms of patients with mild or moderate COVID-19,improve biochemical indicators,and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19.Copyright © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.
RESUMEN
Objective To investigate the correlation between Global Health Security Index (GHSI) and the epidemic situation of COVID-19 and to explore the value of GHSI. Methods A crosssectional study of 159 countries from an open database was conducted. Analyze the correlation of GHSI with the COVID-19 pandemic with Spearman and plot the correlation matrix. Fitted multiple linear regression models controlled for variables such as socioeconomic and health conditions in countries, and further studied the association of GHSI with COVID-19 pandemic outcome indicators. Results The mean total GHSI score of the 159 countries in 2021 was (41. 19+/-13. 41), with a minimum of 16. 10 (Yemen) and a maximum of 75.90 (The United States). As of 31 December 2021, the crude case fatality rate of COVID-19 in 159 countries was 0. 02 (0. 01, 0. 03), with a minimum <0. 01 (Bhutan) and a maximum of 0. 20 (Yemen). The total number of confirmed cases per million population was 50 844.42 (5 807. 88, 101 572.70), with a minimum of 22.26 (Republic of Vanuatu) and a maximum of 251 608. 38 (Slovakia). The total number of deaths per million population was 590. 71 (105. 66,1533. 20), with a minimum of 3. 10 (Burundi) and a maximum of 6 075. 95 (Peru). Multiple linear regression analysis results showed that the Detect score of GHS1 was negatively correlated with the total confirmed cases per million population (fi =-0. 34, P =0. 038) and the total deaths per million population (fi = -0.42, P = 0. 025);the Norms score of GHS1 was negatively correlated with the total confirmed cases per million population (fi = -0. 49, P = 0. 041), and the Health score of GHS1 was positively correlated with the total deaths per million population (fi =0.65, P = 0.003). Risk score of GHS1 was inversely correlated with case fatality rate(fi = -0. 91, P = 0. 044). Conclusion The GHS 1ndex has limited value in assessing a country's capacity to respond to the COV1D-19 pandemic. Nevertheless, it has potential value in others. Copyright © 2022, Publication Centre of Anhui Medical University. All rights reserved.
RESUMEN
［］ Objective： To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 （COVID-19） and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method： The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group，and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms，disappearance time of main symptoms，efficacy on traditional Chinese medicine（TCM）symptoms，hospitalization duration，laboratory test indicators，and CT imaging changes in the two groups were compared. Result： The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment，the disappearance rate of fever，cough， fatigue，dry throat，anorexia，poor mental state，and poor sleep quality in the observation group was higher than that in the control group（P<0.05），and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms，the main symptoms（fever， cough，fatigue，dry throat，anorexia，chest distress）disappeared earlier in the observation group than in the control group（P<0.01）. After 7 days of treatment，the scores of the TCM symptom scale of both groups decreased（P<0.01），and the decrease of the observation group was larger that of the control group（P<0.01）. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group［（12.79±2.68）d］was shorter than that in the control group［（15.27±3.11）d］（P<0.01）. The effective rate in the observation group（92.31%，24/26）was higher than that in the control group（76.92%，20/26）. After 7 days of treatment，the lymphocyte（LYM）count increased（P<0.05），and white blood cell（WBC）count and neutrophil（NEUT）count decreased insignificantly in the two groups. Moreover，levels of C-reactive protein （CRP），erythrocyte sedimentation rate（ESR），and procalcitonin（PCT）reduced in the two groups after treatment（P<0.01）and the reduction in the observation group was larger than that in the control group （P<0.01）. Through 7 days of treatment，the total effective rate on pulmonary shadow in the observation group （90.00%，18/20）was higher than that in the control group（77.27%，17/22）（P>0.05）and the improvement of lung shadow in the observation group was better than that in the control group（P<0.01）. Conclusion：Modified Sanxiaoyin can significantly alleviate fever，cough，fatigue，anorexia，chest distress，poor sleep quality，and other symptoms of patients with mild or moderate COVID-19，improve biochemical indicators，and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19. © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.